Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rxo (RXO) Accumulated Expenses (2021 - 2025)

Historic Accumulated Expenses for Rxo (RXO) over the last 5 years, with Q4 2025 value amounting to $397.0 million.

  • Rxo's Accumulated Expenses rose 643.43% to $397.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $397.0 million, marking a year-over-year increase of 643.43%. This contributed to the annual value of $397.0 million for FY2025, which is 643.43% up from last year.
  • Rxo's Accumulated Expenses amounted to $397.0 million in Q4 2025, which was up 643.43% from $321.0 million recorded in Q3 2025.
  • Rxo's Accumulated Expenses' 5-year high stood at $397.0 million during Q4 2025, with a 5-year trough of $197.0 million in Q2 2024.
  • In the last 5 years, Rxo's Accumulated Expenses had a median value of $262.0 million in 2024 and averaged $275.1 million.
  • As far as peak fluctuations go, Rxo's Accumulated Expenses tumbled by 2226.56% in 2023, and later skyrocketed by 8743.72% in 2024.
  • Rxo's Accumulated Expenses (Quarter) stood at $248.0 million in 2021, then increased by 3.23% to $256.0 million in 2022, then fell by 22.27% to $199.0 million in 2023, then soared by 87.44% to $373.0 million in 2024, then increased by 6.43% to $397.0 million in 2025.
  • Its last three reported values are $397.0 million in Q4 2025, $321.0 million for Q3 2025, and $315.0 million during Q2 2025.